Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load
- PMID: 20736815
- DOI: 10.1097/QAD.0b013e32833e5043
Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load
Abstract
Objective: Few studies have assessed longitudinal genital tract HIV-1 shedding. We determined patterns of genital tract HIV-1 RNA shedding over time among women with suppressed plasma viral load (PVL) on antiretroviral treatment.
Methods: Paired plasma and genital tract HIV-1 RNA were measured every 4 weeks. Participants were classified as persistent, intermittent, or nonshedders. Longitudinal analysis examined rates of genital tract shedding and the association with PVL, CD4 cell count, and genital tract infections. Markov transition models were used to describe the dynamics of HIV-1 RNA in plasma and genital tract using visit-to-visit transitions from and to detectable and undetectable PVL or genital tract HIV-1 RNA.
Results: Fifty-nine women contributed 582 study visits of whom 95 and 98% had below-detectable PVL and genital tract viral load, respectively, at baseline. Thirty-two of 59 women (54%) had detectable HIV-1 RNA at least once in the genital tract. Twenty-two of 59 (37%) women had detectable genital tract HIV-1 RNA during a study visit when PVL was undetectable; 6.8% of the women were persistent shedders, 31% were intermittent shedders, and 45.8% were nonshedders. Sampling three subcompartments increased detection of HIV-1 genital tract viral load compared to sampling a single subcompartment. Overall, genital tract HIV-1 RNA shedding in any subcompartment occurred at about 13% of visits. Shedding in at least one of the three subcompartments occurred at 9% of visits when PVL was undetectable (95% confidence interval 6-14%).
Conclusion: Women with below-detectable PVL may have less risk of HIV sexual transmission on a population level, but may continue to be infectious on an individual level.
Comment in
-
Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load.AIDS. 2011 Mar 27;25(6):880-1. doi: 10.1097/QAD.0b013e328344ccf8. AIDS. 2011. PMID: 21412068 No abstract available.
Similar articles
-
Persistent genital tract HIV-1 RNA shedding after change in treatment regimens in antiretroviral-experienced women with detectable plasma viral load.J Womens Health (Larchmt). 2013 Apr;22(4):330-8. doi: 10.1089/jwh.2012.3849. Epub 2013 Mar 26. J Womens Health (Larchmt). 2013. PMID: 23531097 Free PMC article.
-
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies.AIDS. 2003 Oct 17;17(15):2169-76. doi: 10.1097/00002030-200310170-00004. AIDS. 2003. PMID: 14523273
-
Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding.J Acquir Immune Defic Syndr. 2012 May 1;60(1):99-110. doi: 10.1097/QAI.0b013e31824aeaaa. J Acquir Immune Defic Syndr. 2012. PMID: 22517416 Free PMC article.
-
Recent observations on HIV type-1 infection in the genital tract of men and women.AIDS. 2003 Mar 7;17(4):455-80. doi: 10.1097/00002030-200303070-00001. AIDS. 2003. PMID: 12598766 Review. No abstract available.
-
Detection of human immunodeficiency virus type 1 and type 2 in the female genital tract: implications for the understanding of virus transmission.Obstet Gynecol Surv. 1997 May;52(5):315-24. doi: 10.1097/00006254-199705000-00024. Obstet Gynecol Surv. 1997. PMID: 9140133 Review.
Cited by
-
Evidence of HIV-1 Genital Shedding after One Year of Antiretroviral Therapy in Females Recently Diagnosed in Bamako, Mali.Microorganisms. 2021 Oct 17;9(10):2164. doi: 10.3390/microorganisms9102164. Microorganisms. 2021. PMID: 34683485 Free PMC article.
-
Pharmacology of HIV Cure: Site of Action.Clin Pharmacol Ther. 2021 Apr;109(4):841-855. doi: 10.1002/cpt.2187. Epub 2021 Mar 5. Clin Pharmacol Ther. 2021. PMID: 33540481 Free PMC article. Review.
-
HIV and SIV in Body Fluids: From Breast Milk to the Genitourinary Tract.Curr Immunol Rev. 2019;15(1):139-152. doi: 10.2174/1573395514666180605085313. Curr Immunol Rev. 2019. PMID: 33312088 Free PMC article.
-
The Potential Contribution of Caveolin 1 to HIV Latent Infection.Pathogens. 2020 Oct 27;9(11):896. doi: 10.3390/pathogens9110896. Pathogens. 2020. PMID: 33121153 Free PMC article. Review.
-
Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.PLoS Med. 2020 May 22;17(5):e1003110. doi: 10.1371/journal.pmed.1003110. eCollection 2020 May. PLoS Med. 2020. PMID: 32442189 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grant support
LinkOut - more resources
Full Text Sources
Medical
Research Materials
